Given that genetic and pharmacological inhibition of MKL1 ameliorates AAA formation and the strong induction of MKL1 expression in human AAA tissues, MKL1 represents a promising druggable target for pharmacologic intervention in the prevention and/or treatment of AAA. The gene discussed is MRTFA; the disease is triple-A syndrome.